Maxpro Ventures

With its ongoing Phase 1 clinical trial of ACE1702 for the treatment of HER2-expressing solid tumors, Acepodia hopes to make a case for fast, affordable, and effective off-the-shelf cell therapies.

The company developed a novel human NK cell line, oNK-1, which expresses CD16 and high levels of NK activation markers.

When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. This has earned the industry a lot of respect. The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay. Thes

Advaxis, Inc. completed agreements with two institutional investors to purchase 17,577,400 shares of common stock, 7,671,937 pre-funded warrants, and registered warrants for 11,244,135 additional shares.

ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors.

Anbogen Therapeutics completed its Series A funding round, led by China Development Industrial Bank with contributions from Taian Venture Capital, Maxpro, and the National Development Fund.

Anbogen Therapeutics received the 21st National Innovation Award for its lead asset ABT-301, highlighting its potential in cancer immunotherapy for microsatellite-stable colorectal cancer.

Maxpro Ventures invests in biomedical technology companies, leveraging expertise in biomedical, financial, and operational fields.

a leading biomedical venture capital firm